---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-028072"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:46:11.643312+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex licenses Univ. of Pittsburgh gene therapy for diabetes; milestones up to $4M

## Summary
- Worldwide exclusive license for gene therapy modulating autoimmunity to treat diabetes.
- Genprex pays initial license fee, single-digit running royalties, and low double-digit sublicense income share.
- Milestone payments aggregate up to ~$4M; annual minimum royalties after first commercial sale.
- Licensee must meet development milestones and use diligent efforts to commercialize.
- Agreement term runs 20 years after first commercial sale or expiration of last patent claim.

## SEC filing metadata
- accession: 0001437749-22-028072
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774922028072/0001437749-22-028072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774922028072/gnpx20221024_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-028072
- JSON: https://secwatch.observer/filing/0001437749-22-028072.json
- Plain text: https://secwatch.observer/filing/0001437749-22-028072.txt

## Key facts
- Material Agreements
  Genprex, Inc. entered into UP License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education valued at approximately $4,000,000 (effective 2022-11-22).
  - Action: entry
  - Agreement: license
  - Counterparty: University of Pittsburgh - Of the Commonwealth System of Higher Education
  - Value: approximately $4,000,000
  - Effective: 2022-11-22
  source text: On November 22, 2022, Genprex, Inc. (“Genprex”) and the University of Pittsburgh - Of the Commonwealth System of Higher Education (“UP”) entered into an Exclusive License Agreement (the “UP License Agreement”), pursuant to which UP granted to Genprex a worldwide, exclusive license under certain patents and related technology, referred to collectively as the licensed technology, and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity by gene therapy to affect diabetes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774922028072/0001437749-22-028072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.